Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study

Inflamm Bowel Dis. 2017 Aug;23(8):1272-1277. doi: 10.1097/MIB.0000000000001211.

Abstract

Background: A subset of patients with ulcerative colitis (UC) will require colectomy within a few years of diagnosis. Thus, our aim was to determine the clinical predictors of early colectomy among patients with UC who are hospitalized with an acute flare.

Methods: Using population-based surveillance (1996-2009), all adults (≥18 years) hospitalized for UC within 3 years of diagnosis (n = 489) were identified. The primary outcome was a colectomy within 3 years of diagnosis. All medical charts were reviewed. A logistic regression model evaluated clinical variables that predicted colectomy within 3 years of diagnosis, and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were reported.

Results: Among patients admitted to hospital with UC within 3 years of diagnosis, 57.7% underwent colectomy, with the odds of colectomy decreasing by 12% per year. Early colectomy was more likely among patients aged 35 to 64 years versus 18 to 34 years (OR 2.18 [95% CI, 1.27-3.74]), males (OR 2.03 [95% CI, 1.24-3.34]), those with pancolitis (OR 5.38 [95% CI, 3.20-9.06]), and living in rural areas (OR 2.81 [95% CI, 1.49-5.29]). Prescription of infliximab before hospitalization increased odds of surgery (OR 5.12 [95% CI, 1.36-19.30]).

Conclusions: Patients hospitalized for UC have a high risk of early colectomy. This is particularly true in middle-aged men, those living in rural areas, and those without response to infliximab.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Colectomy / methods*
  • Colectomy / statistics & numerical data*
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / surgery*
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / pharmacology
  • Humans
  • Infliximab / pharmacology*
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Young Adult

Substances

  • Gastrointestinal Agents
  • Infliximab